83 related articles for article (PubMed ID: 19243252)
1. A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.
Tran L; Baars JW; Maessen HJ; Hoefnagel CA; Beijnen JH; Huitema AD
Cancer Biother Radiopharm; 2009 Feb; 24(1):103-10. PubMed ID: 19243252
[TBL] [Abstract][Full Text] [Related]
2. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.
Visser GW; Klok RP; Gebbinck JW; ter Linden T; van Dongen GA; Molthoff CF
J Nucl Med; 2001 Mar; 42(3):509-19. PubMed ID: 11337531
[TBL] [Abstract][Full Text] [Related]
3. 131I-rituximab: relationship between immunoreactivity and specific activity.
Schaffland AO; Buchegger F; Kosinski M; Antonescu C; Paschoud C; Grannavel C; Pellikka R; Delaloye AB
J Nucl Med; 2004 Oct; 45(10):1784-90. PubMed ID: 15471849
[TBL] [Abstract][Full Text] [Related]
4. Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy.
Govindan SV; Griffiths GL; Stein R; Andrews P; Sharkey RM; Hansen HJ; Horak ID; Goldenberg DM
J Nucl Med; 2005 Jan; 46(1):153-9. PubMed ID: 15632046
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
[TBL] [Abstract][Full Text] [Related]
6. Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma.
Natarajan A; Arksey N; Iagaru A; Chin FT; Gambhir SS
Mol Imaging; 2015; 14():. PubMed ID: 25762106
[TBL] [Abstract][Full Text] [Related]
7. Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.
Gholipour N; Vakili A; Radfar E; Jalilian AR; Bahrami-Samani A; Shirvani-Arani S; Ghannadi-Maragheh M
J Cancer Res Ther; 2013; 9(2):199-204. PubMed ID: 23771358
[TBL] [Abstract][Full Text] [Related]
8. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
9. Radioimmunotherapy of MCF7 breast cancer cell line with 131I-PR81 monoclonal antibody against MUC1: comparison of direct and indirect radioiodination methods.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Hasan ZM; Salouti M; Gandomkar M; Sadri K
Hum Antibodies; 2010; 19(1):15-25. PubMed ID: 20555127
[TBL] [Abstract][Full Text] [Related]
10. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
11. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
[TBL] [Abstract][Full Text] [Related]
12. Fully Automated
Poot AJ; Adamzek KWA; Windhorst AD; Vosjan MJWD; Kropf S; Wester HJ; van Dongen GAMS; Vugts DJ
J Nucl Med; 2019 May; 60(5):691-695. PubMed ID: 30530830
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.
Rasaneh S; Rajabi H; Babaei MH; Daha FJ; Salouti M
Nucl Med Biol; 2009 May; 36(4):363-9. PubMed ID: 19423003
[TBL] [Abstract][Full Text] [Related]
14. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
15. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia.
Seitz U; Neumaier B; Glatting G; Kotzerke J; Bunjes D; Reske SN
Eur J Nucl Med; 1999 Oct; 26(10):1265-73. PubMed ID: 10541824
[TBL] [Abstract][Full Text] [Related]
16. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF
Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737
[No Abstract] [Full Text] [Related]
17. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
Pauwels EK; Erba P
Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
[TBL] [Abstract][Full Text] [Related]
18. Lack of tumor uptake of 131-I labeled rituximab in a patient with a CD20 positive lymphoma lesion.
Tran L; Huitema AD; Vogel WV; Beijnen JH; Baars JW
J Oncol Pharm Pract; 2012 Dec; 18(4):417-20. PubMed ID: 22228555
[TBL] [Abstract][Full Text] [Related]
19. An efficient, reproducible and fast preparation of 188Re-anti-CD20 for the treatment of non-Hodgkin's lymphoma.
Ferro-Flores G; Torres-García E; García-Pedroza L; Arteaga de Murphy C; Pedraza-López M; Garnica-Garza H
Nucl Med Commun; 2005 Sep; 26(9):793-9. PubMed ID: 16096583
[TBL] [Abstract][Full Text] [Related]
20. Outpatient 131I-rituximab radioimmunotherapy for non-Hodgkin lymphoma: a study in safety.
Calais PJ; Turner JH
Clin Nucl Med; 2012 Aug; 37(8):732-7. PubMed ID: 22785498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
